16 Recruiting Carcinoma, Renal Cell Clinical Trials
Explore open interventional and observational research studies actively enrolling participants across the USA. Verify eligibility and contact site coordinators directly.
📍 Find Near Me by DistanceBrowse by State
Browse by Study Phase
Top Interventions for Carcinoma, Renal Cell
Top Recruiting Carcinoma, Renal Cell Studies
Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)
📍 University of California at San Francisco ( Site 1008) — San Francisco, California
View Study & Checklist ➔A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
📍 Ironwood Cancer & Research Centers ( Site 0077) — Chandler, Arizona
View Study & Checklist ➔Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)
📍 University of California at San Francisco ( Site 3008) — San Francisco, California
View Study & Checklist ➔A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
📍 The University of Alabama at Birmingham ( Site 0010) — Birmingham, Alabama
View Study & Checklist ➔A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
📍 Mayo Clinic in Arizona - Phoenix ( Site 3554) — Phoenix, Arizona
View Study & Checklist ➔Exploring Relevant Immune-based Biomarkers and Circulating Tumor Cells During Treatment With Immunotherapy in Genitourinary Malignancies (CTC Immune Based Biomarkers)
📍 Duke University Medical Center — Durham, North Carolina
View Study & Checklist ➔A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)
📍 Georgetown University Medical Center ( Site 0002) — Washington D.C., District of Columbia
View Study & Checklist ➔A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
📍 Faculty Office Towers 1132 ( Site 1538) — Birmingham, Alabama
View Study & Checklist ➔A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
📍 Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital ( Site 0102) — Marietta, Georgia
View Study & Checklist ➔Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination With Sunitinib in Patients With TKIs-resistant RCC
📍 UB/ Great Lakes Cancer Care — Buffalo, New York
View Study & Checklist ➔Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
📍 Mayo Clinic Building- Phoenix — Phoenix, Arizona
View Study & Checklist ➔Autologous Dendritic Cell Vaccine in Kidney Cancer
📍 UPMC Department of Urology — Pittsburgh, Pennsylvania
View Study & Checklist ➔Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
📍 University of California Irvine — Orange, California
View Study & Checklist ➔